Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers
- First Online:
To assess the comparative pharmacokinetic profile and bioavailability of docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) after multiple-dose administration of a new oral formulation (test formulation) and a commercially available reference formulation in healthy subjects.
Forty-eight healthy subjects received a 28-day oral treatment with DHA/EPA in the form of either the test or the reference product according to an open-label, randomized, parallel-group design. Both formulations were given t.i.d. at 8-h intervals at a dose of 3.0 g/day. Steady-state DHA and EPA concentrations in plasma and lysed whole blood were measured by gas-liquid chromatography at baseline and after 7, 14, 21 and 28 days of treatment. Kinetic parameters were compared both after subtraction of baseline concentrations and by using baseline concentrations as a covariate.
For both DHA and EPA, plasma and RBC concentrations measured from day 7 to day 28 were significantly higher than at baseline and did not differ significantly between the two products. On day 28 the plasma DHA concentration on average doubled the baseline level after administration of test and reference product, while there was a 10-fold increase in EPA plasma concentration. When the assessment was performed using baseline values as covariate, test-to-reference ratios for area under the curve (AUCss0–8) and for peak concentration (Cssmax) after the last administration on day 28 met bioequivalence criteria (i.e., 90% confidence intervals within 0.80–1.25 for AUCss0–8 ratios, and within 0.75–1.33 for Cssmax ratios). When the assessment was conducted after subtraction of baseline values, the 90% confidence intervals for Cssmax ratios were within the bioequivalence range, whereas the intervals for AUCss0–8 ratio were borderline for bioequivalence.
The two formulations tested were similarly effective in increasing DHA and EPA concentrations in plasma and lysed whole blood, and showed comparable bioavailability for both active components.
KeywordsDocosahexaenoic acid Eicosapentaenoic acid ω-3 fatty acids Bioavailability Humans
- 14.Vidgren HM, Agren JJ, Schwab U, Rissanen T, Hänninen O, Uusitupa MI (1997) Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men. Lipids 32(7):697–705PubMedCrossRefGoogle Scholar
- 20.Department of Health and Human Services and U.S. Department of Agriculture (2005) Dietary guidelines for Americans. http://www.health.gov/DietaryGuidelines/dga2005/document/default.htm. Accessed 18 Dec 2008
- 21.Schuirmann DJ (1990) Design of bioavailability/bioequivalence studies. Drug Inf J 24:315–323Google Scholar
- 22.The European Agency for the Evaluation of Medicinal Products (EMEA) (2001) Note for guidance on the investigation of bioavailability and bioequivalence. Guideline CPMP/EWP/QWP/1401/98. http://www.emea.europa.eu/pdfs/human/qwp/140198en.pdf. Accessed 18 Dec 2008
- 23.U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2003) Guidance for industry—bioavailability and bioequivalence studies for orally administered drug products. General considerations. http://www.fda.gov/Cder/guidance/5356fnl.htm. Accessed 18 Dec 2008
- 24.Food and Drug Administration, Advisory Committee for Pharmaceutical Science (2004) Briefing information: bioequivalence requirements for highly variable drugs and drug products. Washington DCGoogle Scholar
- 29.SAS/STAT user’s guide, version 8.2Google Scholar
- 30.Thermo Electron (2005) Kinetica 4.4.1 user’s manual. Waltham, MAGoogle Scholar